IVACC Intervacc AB (publ)
Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company's product pipeline includes Strangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages in marketing and distribution of veterinary products in the Nordic markets, which includes vaccines and pharmaceuticals for swine, horses, cattle, and sheep. The company was incorporated in 1983 and is based in Hägersten, Sweden.…
Industry Peers
BiotechnologyKey Statistics
About Intervacc (STO: IVACC)
›
Intervacc (STO: IVACC) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 16 employees.
The shares were at 0.6780 SEK on 19 November 2026, down 27.1% over 52 weeks. Its 52-week range is 0.5720 SEK to 1.462 SEK: the price is 53.6% below the high and 18.5% above the low.
Its market capitalisation is 231.07M SEK.
Intervacc reports return on equity of -29.4% and revenue up 12.1% year over year.
It holds more cash than debt, a net cash position of 98.69M SEK. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 2 analysts cover the stock; their mean price target of 1.550 SEK is 128.6% above the current price. The next earnings report is expected on 17 February 2027.